Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KAT8 | Q9H7Z6 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20706357 | 1.00 | ALDH1A1 (0.38) | ALDH1A1KAT8EPHX2ATAD2CECR2 | |
| SCHEMBL13036988 | 0.89 | KAT8 (0.38) | ALDH1A1KAT8EPHX2KMT2A | |
| SCHEMBL16994750 | 0.89 | KAT8 (0.38) | ALDH1A1KAT8EPHX2KMT2A | |
| SCHEMBL12228512 | 0.88 | ALDH1A1 (0.40) | ALDH1A1EPHX2USP30TP53LMNA | |
| SCHEMBL23564478 | 0.85 | KAT5 (0.33) | KAT8EPHX2 | |
| SCHEMBL8426336 | 0.83 | ALDH1A1 (0.40) | ALDH1A1KAT8TP53LMNAKDM4E | |
| SCHEMBL15014638 | 0.82 | TP53 (0.43) | ALDH1A1KAT8TP53HTTMEN1 | |
| SCHEMBL24456475 | 0.82 | TP53 (0.43) | ALDH1A1KAT8TP53HTTMEN1 | |
| SCHEMBL10289418 | 0.82 | TP53 (0.43) | ALDH1A1KAT8TP53HTTMEN1 | |
| SCHEMBL30396227 | 0.82 | ALDH1A1 (0.39) | ALDH1A1KAT8ATAD2CECR2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2021127499-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | ALDH1A1 4227/4885KAT8 1484/4885EPHX2 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.